Find your PDFs fast.
Welcome to the Pubget Medical Subject Headings (MESH) browser. Click on a topic or subtopic below to explore related papers. In the gold box is the most recent paper about the current MESH term, and below are 20 related papers.
Selective Estrogen Receptor Modulators (0):
Recent article
Selective Estrogen Receptor Modulators
Abstract
We discuss the well established data with SERMs, SERDs and AIs, mechanisms underlying resistance and rationale for recycling endocrine compounds and for simultaneously targeting different pathways.
Copyright © 2010 Elsevier Ltd. All rights reserved....
|
PMID: 21129614
PDF is available here.
PDF is available here.
| < More recent | Older article > |
Abstract
The results of recent large clinical trials have led physicians and patients to question the safety of menopausal hormone therapy. In the past, physicians prescribed hormone therapy in an attempt to improve overall health and prevent cardiac disease. Hormone therapy appears to increase the risk of b...
|
PMID: 20879703
PDF is available here.
PDF is available here.
Abstract
Selective estrogen receptor modulators (SERMs) interact with estrogen receptors as agonists or antagonists depending on the target tissue. Currently available SERMs are used to treat and prevent breast cancer and osteoporosis, to treat ovulatory dysfunction in women, and for contraception. Because c...
|
PMID: 20580502
PDF is available here.
PDF is available here.
Abstract
We report a female patient, aged 12 years and 6 months, suffering from juvenile breast hypertrophy, who presented at the third month of symptoms and benefited from tamoxifen treatment.
In experienced clinics, use of tamoxifen in the treatment of juvenile breast hypertrophy during the brisk growth pe...
|
PMID: 20813327
PDF is available here.
PDF is available here.
Oncology Reports (24)3 2010
Abstract
We observed significant decreases in the phosphorylation of the epidermal growth factor receptor (EGFR), AKT, mammalian target of rapamycin (mTOR) and S-6-kinase (S6K), and significant increases in the phosphorylation of stress activated protein kinases (SAPKs). Furthermore, these changes were assoc...
|
PMID: 20664987
PDF is available here.
PDF is available here.
Abstract
We evaluated the effect of estrogen antagonist, raloxifene (Ral), on the prevention and treatment of BPH by investigating its effect on the proliferation of two different prostate cell lines: a stromal cell line, WPMY-1, and a benign prostatic hyperplasia epithelial cell line, BPH-1. We additionally...
|
PMID: 20473319
PDF is available here.
PDF is available here.
Abstract
Even in the post-WHI era, basic and clinical investigation on estrogen and bone will continue to yield important insights that not only expand our knowledge at a basic level but also impact the health of our aging population....
|
PMID: 20685883
PDF is available here.
PDF is available here.
Xenobiotica (40)8 2010
Abstract
Bazedoxifene acetate (BZA), a novel selective estrogen receptor modulator, is currently being developed for the prevention and treatment of osteoporosis in post-menopausal women. In this study, the disposition of BZA was determined in the rat, a pharmacology and safety model. After a single 0.2 mg/k...
|
PMID: 20528166
PDF is available here.
PDF is available here.
Abstract
We have previously demonstrated that prolonged treatments with raloxifene (RAL) in vitro will result in phase II RAL resistance and RAL-induced tumor growth. Clinical interest prompted us to re-examine RAL resistance in vivo, particularly the effects of long-term treatments (a decade or more) on the...
|
PMID: 20596666
PDF is available here.
PDF is available here.
Abstract
We summarize the potential connections between SERMs and EPC biology, uncovering novel possible routes to cardiovascular risk reduction....
|
PMID: 20513233
PDF is available here.
PDF is available here.
Abstract
We have performed pelvic magnetic resonance imaging (MRI) in patients undergoing breast cancer surgery before and after adjuvant drug therapy. Our purpose was to detect any radiographic uterine changes induced by various types of adjuvant therapy on pre- and postmenopausal patients by evaluating pro...
|
PMID: 20661693
PDF is available here.
PDF is available here.
New England Journal of Medicine (362)23 2010
Abstract
New England Journal of Medicine (362)23 2010
Abstract
Abstract
Because atherosclerosis, a leading cause of morbidity and mortality in women, is thought of as a sterol (cholesterol and noncholesterol sterol)-mediated disease, plasma triglyceride (TG) levels (the concentration of all TG trafficked within all of the lipoproteins per dL of plasma), TG biology, and...
|
PMID: 20638625
PDF is available here.
PDF is available here.
Abstract
Endometriosis, a common cause of morbidity in reproductive-age females, results in pelvic pain and infertility. Endometriosis-associated pain can be approached with surgical or medical therapies. Conservative surgery maintains reproductive organs and is effective in the treatment of endometriosis-as...
|
PMID: 20436321
PDF is available here.
PDF is available here.
Abstract
We investigated the effects of raloxifene analogue (LY117018) on cell proliferation and collagen metabolism using cultured rat Achilles tendon fibroblasts. 17beta-Estradiol (E(2); 10(-11)-10(-9) M) and LY117018 (10(-9)-10(-7) M) had no significant effects on tendon fibroblast proliferation, based on...
|
PMID: 20073985
PDF is available here.
PDF is available here.
Abstract
The modulatory effects of E(2) and R at therapeutic doses on GH action are different. R during GH therapy exerts a greater inhibitory effect on lipid oxidation and protein anabolism compared to E(2)....
|
PMID: 20207825
PDF is available here.
PDF is available here.
Abstract
We performed a population-based study in the county of North Jutland, Denmark, including 120 women aged <60 years who received adjuvant chemotherapy with seven cycles of cyclophosphamide, epirubicin and fluoruracil or adjuvant tamoxifen for 6 months for early breast cancer from 2004 to 2006. They we...
|
PMID: 20306129
PDF is available here.
PDF is available here.
Clinical calcium (20)5 2010
Abstract
We have to pay attention to background diseases and life style of the patients....
|
PMID: 20445286
PDF is available here.
PDF is available here.
Clinical calcium (20)5 2010
Abstract
For the treatment of osteoporosis, anti-resorptive agents including bisphosphonates and raloxifene are widely used. As new anti-resorptive drugs, anti-RANKL antibody and cathepsin K inhibitor are under development. Among bone anabolic agents, daily subcutaneous injection of teriparatide will soon be...
|
PMID: 20445281
PDF is available here.
PDF is available here.
Southern Medical Journal (103)4 2010
Abstract
Breast cancer is the most common cancer and the second most common cause of cancer death in women. In 2008 there were 182,460 women diagnosed with breast cancer, and 40,480 women died of this disease. Breast cancer can be prevented by medical (tamoxifen or raloxifene) or surgical approaches (bilater...
|
PMID: 20224493
PDF is available here.
PDF is available here.
Southern Medical Journal (103)4 2010
Abstract
Abstract
About 20% of women reported >or=1 GI SE at entry. GI SEs at month 6 were more common in BP than non-BP users (new: OR = 1.5, 95% CI: 1.2-2.0; stable: OR = 1.7, 95% CI: 1.3-2.1). Women new to OP therapy with GI SEs at month 6 had lower LS Mean HRQoL (OPAQ-SV Emotional Status: 72.3 vs. 78.2, p = 0.005...
|
PMID: 20201623
PDF is available here.
PDF is available here.
Molecular Endocrinology (24)4 2010
Abstract
We investigated the effect of long-term (21 d) hormone replacement on ER signaling by whole-body in vivo imaging. Estrogens and selective ER modulators were administered daily at doses equivalent to those used in humans as calculated by the allometric approach. As controls, ER activity was measured...
|
PMID: 20197311
PDF is available here.
PDF is available here.
Abstract
Oncology Reports (23)4 2010
Abstract
We found that the high passage ER-positive breast cancer MCF7H cells expressed EGFR, HER2 and WT1 at higher levels compared to the low passage MCF7L cells. MCF7H cells responded weakly to estrogen stimulation, grew rapidly in the absence of estrogen and were insensitive to anti-estrogens such as ICI...
|
PMID: 20204298
PDF is available here.
PDF is available here.
Abstract
Aprela, in development by Pfizer Inc, is a once-daily, orally administered, tissue-selective estrogen complex that contains the selective estrogen receptor modulator bazedoxifene (BZA) and conjugated equine estrogens (CE). Aprela was designed as an alternative to combination estrogen and progestin t...
|
PMID: 20336595
PDF is available here.
PDF is available here.
Anticancer Research (30)3 2010
Abstract
In the Br-10 xenografts, CH4986399 (100 mg/kg p.o.) as well as fulvestrant (3 mg/body s.c.) strongly reduced tumor weight. In the ZR-75-1 xenografts, CH4986399 (100 mg/kg p.o.) strongly reduced tumor weight and ER content without agonistic activity. In contrast, tamoxifen (100 mg/kg p.o.) showed onl...
|
PMID: 20393009
PDF is available here.
PDF is available here.
Abstract
Thrombosis and Haemostasis (103)3 2010
Abstract
We report preliminary results obtained with Raloxifene to treat epistaxis in postmenopausal HHT women diagnosed with osteoporosis. We tried to unravel the molecular mechanisms involved in the therapeutic effects of raloxifene. ENG and ACVRL1 genes code for proteins involved in the transforming growt...
|
PMID: 20135064
PDF is available here.
PDF is available here.
Abstract
Abstract
Abstract
Abstract
Abstract
In postmenopausal women, raloxifene gave significantly improved verbal memory when compared with placebo....
|
PMID: 19918203
PDF is available here.
PDF is available here.
Clinical calcium (20)3 2010
Abstract
The 2000 NIH definition of osteoporosis may now call for revision in light of evidence accumulated through clinical studies in the last decade. Of note, as bone quality is now becoming available for evaluation, it is becoming clear that bone quality contributes to bone strength to a far greater degr...
|
PMID: 20190360
PDF is available here.
PDF is available here.
Clinical calcium (20)3 2010
Abstract
Extra-skeletal targets of SERM include the mammary gland and the cardiovascular system. Although raloxifene is exclusively used to treat postmenopausal osteoporosis currently in Japan, large-scale clinical studies have demonstrated that raloxifene is also able to reduce the incidence of invasive bre...
|
PMID: 20190362
PDF is available here.
PDF is available here.
Clinical calcium (20)3 2010
Abstract
We retrospectively investigated changes in bone metabolism in patients with gender identity disorder and Klinefelter's Syndrome. In the patients who had been reassigned from male to female, we observed suppression of bone resorption and increment of BMD, and in the patients who had been reassigned f...
|
PMID: 20190368
PDF is available here.
PDF is available here.
Clinical calcium (20)3 2010
Abstract
Since the aim of the treatment of osteoporosis is to prevent fractures, the first-line drugs must be chosen according to their antifracture efficacies. In postmenopausal women with osteoporosis, alendronate, risedronate, minodronate, and raloxifene are effective in preventing vertebral fractures, an...
|
PMID: 20190370
PDF is available here.
PDF is available here.
Clinical calcium (20)3 2010
Abstract
The therapeutic effect of Raloxifene (RLX) on bone turnover markers was investigated in the elderly women with osteoporosis. The mean age of the control group (< 75 years old) was 67.0 years old, similar to a large-scale clinical trial (MORE study) , and that of the elderly group ( > or =years old)...
|
PMID: 20190372
PDF is available here.
PDF is available here.
Clinical calcium (20)3 2010
Abstract
Osteoporosis is closely associated with lifestyle-related diseases, such as diabetes mellitus, hypertension, and hyperlipidemia. The meta-analysis data reveals that risk of hip fracture is higher in the patients with diabetes mellitus or hypertension compared with those without it. Bone quality more...
|
PMID: 20190361
PDF is available here.
PDF is available here.
Clinical calcium (20)3 2010
Abstract
The bone mass, which is controlled by the balances between bone formation and bone resorption can be reduced by estrogen deficiency in post-menopausal osteoporosis. Reduced bone mass can be recovered by hormone replacement therapy (HRT) , however, HRT has various side effects. Although SERMs can res...
|
PMID: 20190363
PDF is available here.
PDF is available here.
Clinical calcium (20)3 2010
Abstract
Selective Estrogen Receptor Modulators (SERMs) such as raloxifene are characterized as anti-bone resorptive agent as well as bisphosphonate. Recently, bone mass and quality affect bone strength independently. Oxidative stress induced by hyperhomocysteinemia deteriorates bone quality in terms of coll...
|
PMID: 20190364
PDF is available here.
PDF is available here.
Clinical calcium (20)3 2010
Abstract
The effects of treatment with raloxifene on bone quality (proximal femur geometry) are evaluated by hip structure analysis. Raloxifene shows the significant improvement of the index of resistance to bending forces (section modulus) in Japanese patients with postmenopausal osteoporosis. Raloxifene de...
|
PMID: 20190365
PDF is available here.
PDF is available here.
Clinical calcium (20)3 2010
Abstract
Raloxifene is the only SERM available in Japan. The effect on bone metabolism is relatively mild and slow compared with that of bisphosphonates, and reaches plateau after 6th month or later. As diurnal variations of metabolic markers, especially urinary markers are large, it is often difficult to co...
|
PMID: 20190366
PDF is available here.
PDF is available here.
Clinical calcium (20)3 2010
Abstract
The umbrella concept chronic kidney disease-mineral bone and disorders (CKD-MBD) has been developed these days, which includes vascular calcification, laboratory abnormalities, and bone abnormalities. Given the high prevalence of CKD stage 3 in the patients with osteoporosis and the high risk of fra...
|
PMID: 20190367
PDF is available here.
PDF is available here.
Clinical calcium (20)3 2010
Abstract
Raloxifene, a selective estrogen receptor modulator (SERM), was developed with the aim of preventing and treating postmenopausal osteoporosis. Raloxifene is frequently compared to estrogen preparations, and it is considered that besides its actions on the bone, raloxifene also has actions on the ski...
|
PMID: 20190369
PDF is available here.
PDF is available here.
Clinical calcium (20)3 2010
Abstract
It is generally considered that drugs with different pharmacological actions are prescribed when combination therapy is undertaken. Vitamin D insufficiency or deficiency is prevalent in osteopenic and osteoporotic postmenopausal women. Combination therapy of raloxifene with other agents including vi...
|
PMID: 20190371
PDF is available here.
PDF is available here.
Lab Animal (39)2 2010
Abstract
Abstract
Women with early-stage breast cancers that express estrogen and/or progesterone receptors benefit from adjuvant hormonal therapy with antiestrogen drugs. Five years of tamoxifen is the standard to which other approaches have been compared. In premenopausal women, a total of 5 years of adjuvant hormo...
|
PMID: 19952743
PDF is available here.
PDF is available here.
Abstract
We hypothesize that SERMs may be the beneficial selection for patients with CSX....
|
PMID: 20935411
PDF is available here.
PDF is available here.
Abstract
We update our current understanding of stroma-mediated expression of hormones (estrogen) and their role in tumorigenesis, focusing on how aromatase produced in stromal tissue affects tumor cell growth. We also briefly touch on hormone therapy involving selective estrogen receptor modulators and arom...
|
PMID: 20036818
PDF is available here.
PDF is available here.
Acta bio-medica de L'Ateneo parmense : organo della Societa di medicina e scienze naturali di Parma (81 Suppl 1) 2010
Abstract
Osteoporosis is a major and global public health concern. This disorder is characterized by a compromised bone strength and increased susceptibility to fractures, with important health and socioeconomic consequences. Age remains a cardinal, independent determinant of fracture risk; hence, the preval...
|
PMID: 20518192
PDF is available here.
PDF is available here.
Abstract
This review focuses on significant recent findings regarding modulators of androgen and estrogen receptor activity. Selective androgen receptor modulators (SARMs) interact with androgen receptors (ARs), and selective estrogen receptor modulators (SERMs) interact with estrogen recepto...
|
PMID: 21395502
PDF is available here.
PDF is available here.
Abstract
Compared with raloxifene, alendronate did not increase the risk of AF and flutter in women with osteoporosis. Medical history contributed most to the development of AF or AMI in the women who received either raloxifene or alendronate. Long-term treatment with alendronate is not suggested for women w...
|
PMID: 19680161
PDF is available here.
PDF is available here.
Abstract
Selective estrogen receptor modulators (SERMs) have the ability to provide mixed functional estrogen receptor (ER) agonist or antagonist activity, depending on the target tissue. Tamoxifen, the first SERM available for clinical use, is regarded as a highly effective agent for the prevention and trea...
|
PMID: 20107426
PDF is available here.
PDF is available here.
Abstract
Abstract
Ospemifene was shown to be effective and well tolerated for the treatment of the symptoms of vaginal dryness and dyspareunia associated with vulvovaginal atrophy over and above the use of provided lubricants....
|
PMID: 20032798
PDF is available here.
PDF is available here.
Abstract
Presently, no clinical recommendations can be made with regard to RLX and its effects on breast density. To determine the effect of RLX on breast density, larger studies need to be conducted in postmenopausal women with high breast density at baseline who are at high risk for BC, with a standardized...
|
PMID: 20032799
PDF is available here.
PDF is available here.
Abstract
Long-term treatment with RAL can reduce the severity of MI-induced arrhythmias and attenuate MI/R-induced damages and apoptosis in Ovx rats. This cardioprotective effect of RAL may be associated with inhibition of neutrophil infiltration and suppression of nuclear factor-kappaB activation....
|
PMID: 19745773
PDF is available here.
PDF is available here.